ArticleESC heart failure2025
Cardiac magnetic resonance left atrioventricular coupling index as a prognostic tool in hypertrophic cardiomyopathy.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cardiovascular magnetic resonance-derived left atrioventricular coupling index for predicting adverse cardiac outcomes in patients with ischemic cardiomyopathy.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Article
- Left Atrioventricular Coupling Index in Feline Hypertrophic Cardiomyopathy: Association with Disease Severity and Arterial Thromboembolism.Veterinary sciences · 2026Article
- Prognostic value of the left atrioventricular coupling index for adverse cardiac outcomes in hypertrophic cardiomyopathy.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Echocardiographic assessment of left atrioventricular coupling index: technical approaches and clinical implementation strategies.Frontiers in cardiovascular medicine · 2026Review
- Prognostic impact of cardiovascular magnetic resonance-derived left atrioventricular coupling Index in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.European heart journal. Imaging methods and practice · 2026Article
- Anthracycline-induced left atrioventricular dyssynchrony in children with leukemia: a cardiac magnetic resonance imaging study of functional and strain analysis.Frontiers in cardiovascular medicine · 2026Article
- Left Atrial Coupling Index for the Prediction of Atrial Fibrillation and Heart Failure: Current Evidence and Clinical Implications.Current cardiology reports · 2025Review
- Cardiac magnetic resonance left atrioventricular coupling index as a prognostic tool in hypertrophic cardiomyopathy.ESC heart failure · 2025Article
- The power of the left atrioventricular coupling index in cardiovascular disease.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsA novel marker left atrioventricular coupling index (LACI) has been proved to be associated with cardiovascular events in patients without history of cardiovascular disease. However, the studies on cardiac magnetic resonance-derived LACI in hypertrophic cardiomyopathy (HCM) patients are limited, and the prognostic value of LACI has still not been studied thoroughly, so we aimed to explore the association between LACI and adverse clinical outcomes in HCM patients.
methodsA total of 206 HCM patients underwent cardiac magnetic resonance examination were retrospectively enrolled. LACI is defined by the ratio between the left atrial (LA) volume and the left ventricular (LV) volume in LV end-diastolic phase. The composite endpoint was categorized into death-related, heart failure-related, and arrhythmia-related events, reflecting mortality risk, heart failure progression, and arrhythmia burden, respectively. Receiver operating characteristics curve analysis was used to determine the optimal cut-off value for LACI to distinguish HCM patients at high risk of adverse clinical outcome. Multivariable Cox regression models were built including significant clinical variables, LA ejection fraction (LAEF), LA volume index (LAVI), late gadolinium enhancement (LGE) extent and LACI. The improvement of discrimination by adding LACI to a clinical model was assessed using C-statistic, net reclassification improvement (NRI) and integrated discrimination improvement (IDI).
resultsThirty-four HCM patients reached the endpoint during a median follow-up time of 60 [interquartile range (50-68)] months. In the multivariate Cox regression analysis, LACI [hazard ratio 1.054, 95% confidence interval (CI): 1.037, 1.071; P < 0.001] was an independent predictor of the composite events after adjustment for age and atrial fibrillation. Then 40.09% was identified as an optimal cut-off for LACI in the risk stratification. Integrating LACI to the clinical model yielded higher C-statistic 0.892 with 95% CI (0.861, 0.922) compared with LA diameter, LAEF, LAVI and LGE extent, providing an improvement in prediction of high-risk patients (NRI = 0.627, 95% CI: 0.112-0.934; IDI = 0.295, 95% CI: 0.016-0.709).
conclusionsLACI is an independent risk factor for clinical adverse outcome and is superior to conventional LA parameters and LGE extent for the identification of high-risk HCM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.